Mon Nov 25 12:20:00 UTC 2024: ## Cassava Sciences to Host Conference Call on Alzheimer’s Drug Simufilam

**AUSTIN, Texas (November 24, 2024)** – Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company, announced today it will hold a conference call and webcast on Monday, November 25th at 8:00 a.m. ET to discuss updates on its Alzheimer’s disease treatment, Simufilam. The call will provide an update on the Phase 3 clinical trials currently underway for this investigational drug. A replay of the webcast will be available on the company website for 90 days. Simufilam is an oral, small molecule drug targeting the filamin A protein. Cassava Sciences holds exclusive worldwide rights to Simufilam.

Read More